Trial Profile
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Apr 2024
Price :
$35
*
At a glance
- Drugs Polatuzumab vedotin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; T-cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms POLARIX
- Sponsors Chugai Pharmaceutical; Genentech; Roche
- 15 Mar 2024 Planned End Date changed from 30 Jun 2024 to 27 Jun 2024.
- 15 Mar 2024 Planned primary completion date changed from 30 Jun 2024 to 27 Jun 2024.
- 12 Dec 2023 Results of post hoc exploratory analysis (n=594) assessing the prevalence and clinical outcomes of molecularly defined subtypes of DLBCL in pts treated with Pola-R-CHP vs R-CHOP presented at the 65th American Society of Hematology Annual Meeting and Exposition